Cassava Sciences, Inc.

Mr. Michael  Zamloot

Senior Vice President of Technical Operations

Mr. Richard Jon Barry

Chief Executive Officer, President & Director

Dr. James W. Kupiec M.D.

Chief Medical Officer

Dr. Michael  Marsman Pharm.D.

Senior Vice President of Regulatory Affairs

Ms. Freda  Nassif

Chief Commercial Officer

Jaren  Landen

Chief Clinical Development Officer

Dr. George  Thornton Ph.D.

Senior Vice President of Technology

Mr. R. Christopher Cook J.D.

Senior Vice President, Company Secretary & General Counsel

Mr. Eric J. Schoen

Chief Financial Officer

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

NEW YORK, NY / ACCESSWIRE / December 23, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=118111&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA

NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").

SAVA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

NEW YORK , Dec. 23, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA

NEW YORK, NY / ACCESSWIRE / December 22, 2024 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=117985&wire=1 or contact Joseph E. Levi, Esq.

Cassava Sciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights - SAVA

NEW YORK, NY / ACCESSWIRE / December 22, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").

SAVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Cassava Sciences, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

Cassava Sciences, Inc.SAVA

Cassava Sciences, Inc.
SAVA